🏥 治験ポータル
← 治験一覧に戻る

ウイルス関連腫瘍におけるニボルマブおよびニボルマブ併用療法の安全性と有効性を調査する治験免疫療法研究

基本情報

NCT ID
NCT02488759
ステータス
完了
試験のフェーズ
第1/第2相
試験タイプ
介入
目標被験者数
578
治験依頼者名
Bristol-Myers Squibb

概要

The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: * Anal canal cancer-No longer enrolling this tumor type * Cervical cancer * Epstein Barr Virus (EBV) positive gastric cancer-No longer enrolling this tumor type * Merkel Cell Cancer * Penile cancer-No longer enrolling this tumor type * Vaginal and vulvar cancer-No longer enrolling this tumor type * Nasopharyngeal Cancer - No longer enrolling this tumor type * Head and Neck Cancer - No longer enrolling this tumor type

対象疾患

Various Advanced Cancer

介入

Nivolumab(DRUG)
Ipilimumab(DRUG)
Relatlimab(DRUG)
Daratumumab(DRUG)